Literature DB >> 21054151

Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005: an analysis of 21 734 cases.

Faiha Bazzeh1, Rawad Rihani, Scott Howard, Iyad Sultan.   

Abstract

We analyzed data from 18 898 adults (age ≥20 years) and 2836 children/adolescents reported in the Surveillance, Epidemiology and End Results (SEER) database as having Hodgkin lymphoma (HL), diagnosed from 1988 to 2005. The nodular sclerosis subtype was significantly more common in the pediatric age group (76% in children/adolescents vs. 61% in adults, p < 0.001). The mixed cellularity subtype was more prevalent in children <10 years old (22%), but less likely in older children/adolescents (8.5%). Systemic symptoms were reported in 39% of children/adolescents and in 48% of adults (p < 0.001). Children/adolescents had significantly better HL-specific survival than adults (5-year survival rate, 96% ± 0.4% vs.88% ± 0.3%, p < 0.001). Using a Cox proportional-hazards regression model in patients with classical HL, the prognostic factors significantly impacting survival were age, histology, stage, B symptoms, year of diagnosis, and race. The only adverse prognostic factors that were significant when this analysis was restricted to children/adolescents were stage IV disease and the presence of B symptoms. In conclusion, several differences in clinicopathologic features and outcomes were identified between children/adolescents and adults with HL, and this was particularly noted in young children (<10 years).

Entities:  

Mesh:

Year:  2010        PMID: 21054151     DOI: 10.3109/10428194.2010.525724

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  18 in total

Review 1.  Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Authors:  Catherine S Diefenbach; Joseph M Connors; Jonathan W Friedberg; John P Leonard; Brad S Kahl; Richard F Little; Lawrence Baizer; Andrew M Evens; Richard T Hoppe; Kara M Kelly; Daniel O Persky; Anas Younes; Lale Kostakaglu; Nancy L Bartlett
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

2.  ABVD chemotherapy with reduced radiation therapy rates in children, adolescents and young adults with all stages of Hodgkin lymphoma.

Authors:  K C Marr; J M Connors; K J Savage; K J Goddard; R J Deyell
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

3.  Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group.

Authors:  Cindy L Schwartz; Lu Chen; Kathleen McCarten; Suzanne Wolden; Louis S Constine; Robert E Hutchison; Pedro A de Alarcon; Frank G Keller; Kara M Kelly; Tanya A Trippet; Stephan D Voss; Debra L Friedman
Journal:  Pediatr Blood Cancer       Date:  2016-10-27       Impact factor: 3.167

4.  Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials.

Authors:  Justine M Kahn; Qinglin Pei; Debra L Friedman; Joel Kaplan; Frank G Keller; David Hodgson; Yue Wu; Burton E Appel; Smita Bhatia; Tara O Henderson; Cindy L Schwartz; Kara M Kelly; Sharon M Castellino
Journal:  Lancet Haematol       Date:  2022-01       Impact factor: 18.959

Review 5.  Advances in CD30- and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma.

Authors:  Huimin Ma; Xin Li; Meng Lin; Kebing Lv; Mingzhi Zhang; Xiaolong Wu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

6.  Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma.

Authors:  Sachin R Jhawar; Zorimar Rivera-Núñez; Richard Drachtman; Peter D Cole; Bradford S Hoppe; Rahul R Parikh
Journal:  JAMA Oncol       Date:  2019-05-01       Impact factor: 31.777

7.  Scaling up cancer care for children without medical insurance in developing countries: The case of Mexico.

Authors:  Ricardo Pérez-Cuevas; Svetlana V Doubova; Marta Zapata-Tarres; Sergio Flores-Hernández; Lindsay Frazier; Carlos Rodríguez-Galindo; Gabriel Cortes-Gallo; Salomon Chertorivski-Woldenberg; Onofre Muñoz-Hernández
Journal:  Pediatr Blood Cancer       Date:  2012-08-08       Impact factor: 3.167

8.  Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031.

Authors:  Sarah A Milgrom; Jihyun Kim; Alin Chirindel; Jongho Kim; Qinglin Pei; Lu Chen; Allen Buxton; Sandy Kessel; Jeffrey Leal; Kathleen M McCarten; Bradford S Hoppe; Suzanne L Wolden; Cindy L Schwartz; Debra L Friedman; Kara M Kelly; Steve Y Cho
Journal:  Pediatr Blood Cancer       Date:  2021-07-10       Impact factor: 3.838

9.  Hodgkin lymphoma--a survey of children and adolescents treated in Sweden 1985-2009.

Authors:  Annika Englund; Charlotte Hopstadius; Gunilla Enblad; Göran Gustafsson; Gustaf Ljungman
Journal:  Acta Oncol       Date:  2014-09-09       Impact factor: 4.089

10.  Overview and outcome of Hodgkin's Lymphoma: Experience of a single developing country's oncology centre.

Authors:  Rawand P Shamoon; Mohamad Dahir Ali; Nazar P Shabila
Journal:  PLoS One       Date:  2018-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.